TuHURA Biosciences (NASDAQ:HURA) Issues Earnings Results

by · The Cerbat Gem

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) posted its earnings results on Friday. The company reported $999.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $999.12, reports.

TuHURA Biosciences Price Performance

Shares of HURA traded down $0.20 during trading hours on Friday, reaching $2.31. 613,892 shares of the company’s stock traded hands, compared to its average volume of 1,470,507. The firm has a market capitalization of $147.10 million, a price-to-earnings ratio of -3.67 and a beta of -0.01. TuHURA Biosciences has a twelve month low of $0.41 and a twelve month high of $4.05. The business’s fifty day simple moving average is $2.13 and its two-hundred day simple moving average is $1.61.

Analysts Set New Price Targets

A number of research firms have issued reports on HURA. Citigroup began coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating on the stock. Citizens Jmp began coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 target price on the stock. Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Get Our Latest Analysis on HURA

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HURA. Geode Capital Management LLC grew its holdings in TuHURA Biosciences by 111.4% during the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after acquiring an additional 307,260 shares during the period. Deutsche Bank AG grew its holdings in TuHURA Biosciences by 209.8% during the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after acquiring an additional 54,051 shares during the period. New York State Common Retirement Fund acquired a new position in TuHURA Biosciences during the second quarter worth about $97,000. Goldman Sachs Group Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth about $30,000. Finally, Marshall Wace LLP acquired a new position in TuHURA Biosciences during the second quarter worth about $79,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

Recommended Stories